Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan Brown

Showing results (91-100 of 96) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 96 results.
Chemical Society Reviews|July 2, 2021
A critical overview of computational approaches employed for COVID-19 drug discoveryEugene N Muratov, Rommie Amaro, Carolina H Andrade, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 27, 2019
Technoeconomic and life-cycle analysis of single-step catalytic conversion of wet ethanol into fungible fuel blendstocksJohn R Hannon, Lee R Lynd, Onofre Andrade, et al.
Journal of Medicinal Chemistry|October 10, 2012
Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemiaVassilios Bavetsias, Simon Crumpler, Chongbo Sun, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Once yearly cell-based therapy for sustained and dose tunable delivery of monoclonal antibodiesCody Fell, Anthony E Davis, Shalini Pandey, et al.
ACS Medicinal Chemistry Letters|January 8, 2019
Privileged Structures and Polypharmacology within and between Protein FamiliesJoshua Meyers, Nicola E A Chessum, Salyha Ali, et al.
Journal of Medicinal Chemistry|May 12, 2016
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)James D Osborne, Thomas P Matthews, Tatiana McHardy, et al.
Pageof 10

Showing results (91-100 of 96) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 96 results.
Chemical Society Reviews|July 2, 2021
A critical overview of computational approaches employed for COVID-19 drug discoveryEugene N Muratov, Rommie Amaro, Carolina H Andrade, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 27, 2019
Technoeconomic and life-cycle analysis of single-step catalytic conversion of wet ethanol into fungible fuel blendstocksJohn R Hannon, Lee R Lynd, Onofre Andrade, et al.
Journal of Medicinal Chemistry|October 10, 2012
Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemiaVassilios Bavetsias, Simon Crumpler, Chongbo Sun, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Once yearly cell-based therapy for sustained and dose tunable delivery of monoclonal antibodiesCody Fell, Anthony E Davis, Shalini Pandey, et al.
ACS Medicinal Chemistry Letters|January 8, 2019
Privileged Structures and Polypharmacology within and between Protein FamiliesJoshua Meyers, Nicola E A Chessum, Salyha Ali, et al.
Journal of Medicinal Chemistry|May 12, 2016
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)James D Osborne, Thomas P Matthews, Tatiana McHardy, et al.
Pageof 10